These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 19895813)

  • 1. Improved in vitro methods to predict the in vivo toxicity in man of therapeutic monoclonal antibodies including TGN1412.
    Findlay L; Eastwood D; Stebbings R; Sharp G; Mistry Y; Ball C; Hood J; Thorpe R; Poole S
    J Immunol Methods; 2010 Jan; 352(1-2):1-12. PubMed ID: 19895813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of novel methods for predicting the risk of pro-inflammatory clinical infusion reactions during monoclonal antibody therapy.
    Findlay L; Eastwood D; Ball C; Robinson CJ; Bird C; Wadhwa M; Thorpe SJ; Thorpe R; Stebbings R; Poole S
    J Immunol Methods; 2011 Aug; 371(1-2):134-42. PubMed ID: 21741383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endothelial cells co-stimulate peripheral blood mononuclear cell responses to monoclonal antibody TGN1412 in culture.
    Findlay L; Sharp G; Fox B; Ball C; Robinson CJ; Bird C; Stebbings R; Eastwood D; Wadhwa M; Poole S; Thorpe R; Thorpe SJ
    Cytokine; 2011 Jul; 55(1):141-51. PubMed ID: 21493088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells.
    Eastwood D; Findlay L; Poole S; Bird C; Wadhwa M; Moore M; Burns C; Thorpe R; Stebbings R
    Br J Pharmacol; 2010 Oct; 161(3):512-26. PubMed ID: 20880392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody C region influences TGN1412-like functional activity in vitro.
    Ball C; Fox B; Hufton S; Sharp G; Poole S; Stebbings R; Eastwood D; Findlay L; Parren PW; Thorpe R; Bristow A; Thorpe SJ
    J Immunol; 2012 Dec; 189(12):5831-40. PubMed ID: 23150712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A simple whole blood bioassay detects cytokine responses to anti-CD28SA and anti-CD52 antibodies.
    Bailey L; Moreno L; Manigold T; Krasniqi S; Kropshofer H; Hinton H; Singer T; Suter L; Hansel TT; Mitchell JA
    J Pharmacol Toxicol Methods; 2013; 68(2):231-239. PubMed ID: 23280407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Were monocytes responsible for initiating the cytokine storm in the TGN1412 clinical trial tragedy?
    Sandilands GP; Wilson M; Huser C; Jolly L; Sands WA; McSharry C
    Clin Exp Immunol; 2010 Dec; 162(3):516-27. PubMed ID: 20964641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preculture of PBMCs at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412.
    Römer PS; Berr S; Avota E; Na SY; Battaglia M; ten Berge I; Einsele H; Hünig T
    Blood; 2011 Dec; 118(26):6772-82. PubMed ID: 21931118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. After TGN1412: recent developments in cytokine release assays.
    Stebbings R; Eastwood D; Poole S; Thorpe R
    J Immunotoxicol; 2013; 10(1):75-82. PubMed ID: 22967038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A whole blood in vitro cytokine release assay with aqueous monoclonal antibody presentation for the prediction of therapeutic protein induced cytokine release syndrome in humans.
    Wolf B; Morgan H; Krieg J; Gani Z; Milicov A; Warncke M; Brennan F; Jones S; Sims J; Kiessling A
    Cytokine; 2012 Dec; 60(3):828-37. PubMed ID: 22986013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Signaling signatures and functional properties of anti-human CD28 superagonistic antibodies.
    Waibler Z; Sender LY; Merten C; Hartig R; Kliche S; Gunzer M; Reichardt P; Kalinke U; Schraven B
    PLoS One; 2008 Mar; 3(3):e1708. PubMed ID: 18320029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A predictive biomimetic model of cytokine release induced by TGN1412 and other therapeutic monoclonal antibodies.
    Dhir V; Fort M; Mahmood A; Higbee R; Warren W; Narayanan P; Wittman V
    J Immunotoxicol; 2012; 9(1):34-42. PubMed ID: 22074378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human regulatory T cells are selectively activated by low-dose application of the CD28 superagonist TGN1412/TAB08.
    Tabares P; Berr S; Römer PS; Chuvpilo S; Matskevich AA; Tyrsin D; Fedotov Y; Einsele H; Tony HP; Hünig T
    Eur J Immunol; 2014 Apr; 44(4):1225-36. PubMed ID: 24374661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of a novel fully human non-superagonistic anti-CD28 antibody with efficient and safe T-cell co-stimulation properties.
    Elsayed A; Pellegrino C; Plüss L; Peissert F; Benz R; Ulrich F; Thorhallsdottir G; Plaza SD; Villa A; Mock J; Puca E; De Luca R; Manz MG; Halin C; Neri D
    MAbs; 2023; 15(1):2220839. PubMed ID: 37288872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. "Cytokine storm" in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics.
    Stebbings R; Findlay L; Edwards C; Eastwood D; Bird C; North D; Mistry Y; Dilger P; Liefooghe E; Cludts I; Fox B; Tarrant G; Robinson J; Meager T; Dolman C; Thorpe SJ; Bristow A; Wadhwa M; Thorpe R; Poole S
    J Immunol; 2007 Sep; 179(5):3325-31. PubMed ID: 17709549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytokine release assays for the prediction of therapeutic mAb safety in first-in man trials--Whole blood cytokine release assays are poorly predictive for TGN1412 cytokine storm.
    Vessillier S; Eastwood D; Fox B; Sathish J; Sethu S; Dougall T; Thorpe SJ; Thorpe R; Stebbings R
    J Immunol Methods; 2015 Sep; 424():43-52. PubMed ID: 25960173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An autologous endothelial cell:peripheral blood mononuclear cell assay that detects cytokine storm responses to biologics.
    Reed DM; Paschalaki KE; Starke RD; Mohamed NA; Sharp G; Fox B; Eastwood D; Bristow A; Ball C; Vessillier S; Hansel TT; Thorpe SJ; Randi AM; Stebbings R; Mitchell JA
    FASEB J; 2015 Jun; 29(6):2595-602. PubMed ID: 25746794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of a TGN1412 analogue using in vitro assays and two immune humanized mouse models.
    Yan H; Bhagwat B; Sanden D; Willingham A; Tan A; Knapton AD; Weaver JL; Howard KE
    Toxicol Appl Pharmacol; 2019 Jun; 372():57-69. PubMed ID: 30914376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human Fcγ receptors compete for TGN1412 binding that determines the antibody's effector function.
    Dudek S; Weißmüller S; Anzaghe M; Miller L; Sterr S; Hoffmann K; Hengel H; Waibler Z
    Eur J Immunol; 2019 Jul; 49(7):1117-1126. PubMed ID: 31002172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severity of the TGN1412 trial disaster cytokine storm correlated with IL-2 release.
    Eastwood D; Bird C; Dilger P; Hockley J; Findlay L; Poole S; Thorpe SJ; Wadhwa M; Thorpe R; Stebbings R
    Br J Clin Pharmacol; 2013 Aug; 76(2):299-315. PubMed ID: 23701319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.